Images
Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Link to Innovaspain.com
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
